DENVER, Jan. 20, 2026 /PRNewswire/ — Haims Capital, a financial technology firm specializing in data-driven investment analytics, announced plans to launch RKM DENVER, Jan. 20, 2026 /PRNewswire/ — Haims Capital, a financial technology firm specializing in data-driven investment analytics, announced plans to launch RKM

Haims Capital to Launch RKM 6.0 Investment System for U.S. Market

2026/01/20 17:45
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

DENVER, Jan. 20, 2026 /PRNewswire/ — Haims Capital, a financial technology firm specializing in data-driven investment analytics, announced plans to launch RKM 6.0, the latest version of its Real-time Kernel Matrix (RKM) intelligent investment decision system, in June 2026. The updated platform is designed to support investors in the U.S. market by integrating real-time market data, behavioral finance analysis, and adaptive learning models into a unified decision-support framework amid increasingly complex and volatile global market conditions.

The launch comes amid continued volatility across global financial markets, shaped by evolving monetary policy, regulatory adjustments, technological shifts, and geopolitical developments. According to Haims Capital, these conditions have increased demand for analytical tools that help investors process complex data signals while reducing the influence of emotional bias on investment decisions.

RKM 6.0 builds on the system’s existing three-layer architecture, combining real-time market signal processing, behavioral finance modeling, and adaptive learning mechanisms that adjust analytical outputs as market conditions evolve. The company stated that earlier versions of the system were evaluated through internal testing scenarios involving U.S. equity market conditions, interest-rate fluctuations, regulatory developments, and sector-specific market movements.

“As U.S. markets continue to adjust to shifting monetary policy and heightened volatility, investors are seeking analytical tools that can help interpret real-time signals without amplifying emotional bias,” said Daniel Hartwin, Marketing Manager at Haims Capital. “RKM 6.0 reflects our ongoing effort to enhance adaptive analysis and risk awareness while maintaining transparency in how insights are generated.”

Expanded Data Integration and System Enhancements

According to the company, RKM 6.0 expands its data coverage to include a broader range of real-time indicators, such as macroeconomic signals, market sentiment inputs, supply-chain activity, and alternative datasets. This approach is intended to support analysis during periods when traditional data sources may be delayed or incomplete.

The updated system also introduces refinements to its behavioral finance components, designed to identify common investor biases—such as loss aversion or herd behavior—during periods of heightened market volatility. These insights are presented as decision-support signals rather than automated trade instructions.

In addition, Haims Capital reported that RKM 6.0 incorporates an updated adaptive learning framework intended to improve scenario analysis and probability modeling during rapidly changing market conditions. The company emphasized that outputs are designed to assist human decision-making rather than replace it.

Applications Across Market Scenarios

Haims Capital noted that recent market developments—including regulatory changes affecting the U.S. financial sector and increased activity in technology-driven industries—have underscored the need for tools capable of monitoring systemic risk alongside opportunity signals. The company stated that RKM 6.0 is designed to help users assess such conditions by combining market indicators with risk-management analytics.

The platform is also being positioned for use in educational and analytical contexts. Through the Haims Capital Foundation, the company plans to incorporate elements of RKM 6.0 into financial literacy initiatives aimed at improving access to data-driven investment education.

About Haims Capital

Haims Capital is a financial technology company focused on developing analytical systems that support investment decision-making through real-time data integration, behavioral finance insights, and adaptive modeling frameworks. Operating across North America and international markets, the company supports professional, institutional, and educational initiatives related to data-driven investment analysis.

For more information about RKM 6.0, users can visit https://www.haims.ai.

Contact:
Haims Capital
[email protected] 

Photo: https://mma.prnewswire.com/media/2865138/Haims_Capital.jpg
Photo: https://mma.prnewswire.com/media/2865139/Haims_Capital.jpg
Logo: https://mma.prnewswire.com/media/2865140/Haims_Capital_Logo.jpg

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haims-capital-to-launch-rkm-6-0-investment-system-for-us-market-302665236.html

SOURCE Haims Capital

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09